Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)

Soomro, G M; Altman, Douglas G.; Rajagopal, Sundararajan; Oakley‐Browne, Mark

doi:10.1002/14651858.cd001765.pub3

Cited by 222 publications

(197 citation statements)

References 87 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…The findings of systematic reviews and meta-analyses of randomised double-blind placebo-controlled trials indicate that the TCA antidepressant clomipramine, and the SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) [I (M)] (Soomro et al, 2008) are all efficacious in acute treatment, in reducing symptom severity and in improving health-related quality of life [IV] (Fineberg et al, 2012 (Fineberg and Gale, 2005). The findings of a randomised comparator controlled trial suggest that paroxetine and venlafaxine had comparable effectiveness and acceptability [II] (Denys et al, 2003).…”

Section: Acute Treatment Of Obsessivecompulsive Disordermentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

Section: Acute Treatment Of Obsessivecompulsive Disordermentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Citalopram is an often-prescribed drug for not only depression (Cipriani et al, 2009) but also various other disorders like PTSD (Hetrick et al, 2010) and OCD (Soomro et al, 2008). To understand the potential efficiency of a drug, it is important to uncover its neural mechanism of action.…”

Section: Escitalopram Effects In Iedmentioning

confidence: 99%

Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study

Cremers

Lee

Keedy

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

The neurobiological underpinnings of intermittent explosive disorder (IED) are traditionally linked to deficiencies in the serotonergic system. In this study, we investigated the effects of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on brain activation during face processing. We expected that escitalopram would reduce amygdala activity in IED and in addition, we explored the effect in other social-emotional-related brain regions. A total of 17 subjects with current IED and 14 healthy controls participated in a randomized, double-blind, placebo-controlled, counterbalanced fMRI face processing study. The analysis focused on the faces compared to a fixation baseline contrast, and a factorial model with Group as between-subject and Drug as within-subject factor was tested. Group × Drug interaction effects were found in the amygdala (small volume corrected) and the left temporal parietal junction (TPJ; whole-brain corrected). Escitalopram increased amygdala activation in controls, but surprisingly not in IED. However, the TPJ showed increased activity in IED on escitalopram compared with placebo. The TPJ is associated with social-cognitive processes, such as perspective taking and empathy. The TPJ findings suggest that SSRI administration may reduce aggressive tendencies towards other people by enhancing these social-cognitive processes. Future research should further elucidate the long-term effects of SSRIs on various social-emotional tasks in IED.

show abstract

“…Due to the adverse effects commonly observed in people treated with clomipramine, selective serotonin reuptake inhibitors (SSRIs) have taken over clomipramine as the first-line agents in the treatment of OCD. Several RCTs have consistently demonstrated the efficacy of SSRIs in the treatment of OCD [8], albeit at a higher than usual antidepressant dosage and a longer time (8)(9)(10)(11)(12) weeks) for improvement [9].…”

Section: Reviewmentioning

confidence: 99%

Augmentation strategies in obsessive–compulsive disorder

Arumugham

Reddy

2013

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)

Abstract: Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Cited by 222 publications

References 87 publications

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study

Augmentation strategies in obsessive–compulsive disorder

Contact Info

Product

Resources

About